20/20 Biolabs, Inc. Common Stock (AIDX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, 20/20 Biolabs, Inc. Common Stock (AIDX) has a cash flow conversion efficiency ratio of -0.350x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-536.45K) by net assets ($1.53 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of 20/20 Biolabs, Inc. Common Stock to measure how many days the company can operate on defensive assets alone.
20/20 Biolabs, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how 20/20 Biolabs, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
20/20 Biolabs, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of 20/20 Biolabs, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Avenir Telecom S.A
PA:AVT
|
-3.784x |
|
Pila Pharma AB
ST:PILA
|
-0.129x |
|
Agrogalaxy Participacoes SA
SA:AGXY3
|
-0.339x |
|
Chiangmai Rimdoi Public Company Limited
BK:CRD
|
0.179x |
|
REGENER8 Resources NL
AU:R8R
|
-0.120x |
|
MOSTOSTAL Płock SA
WAR:MSP
|
-0.174x |
|
CEA Industries Inc
NASDAQ:CEAD
|
-0.091x |
|
Smart Powerr Corp
NASDAQ:CREG
|
0.017x |
Annual Cash Flow Conversion Efficiency for 20/20 Biolabs, Inc. Common Stock (2016–2024)
The table below shows the annual cash flow conversion efficiency of 20/20 Biolabs, Inc. Common Stock from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see market value of 20/20 Biolabs, Inc. Common Stock.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.53 Million | $-2.60 Million | -1.694x | -56.91% |
| 2023-12-31 | $4.29 Million | $-4.63 Million | -1.080x | -274.38% |
| 2022-12-31 | $9.37 Million | $5.80 Million | 0.619x | +497.12% |
| 2021-12-31 | $6.89 Million | $-1.07 Million | -0.156x | +74.07% |
| 2020-12-31 | $3.39 Million | $-2.04 Million | -0.601x | +39.14% |
| 2019-12-31 | $2.15 Million | $-2.12 Million | -0.988x | -146.80% |
| 2018-12-31 | $3.28 Million | $-1.31 Million | -0.400x | +82.79% |
| 2017-12-31 | $456.18K | $-1.06 Million | -2.325x | +3.73% |
| 2016-12-31 | $784.36K | $-1.89 Million | -2.415x | -- |
About 20/20 Biolabs, Inc. Common Stock
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (… Read more